½ÃÀ庸°í¼­
»óǰÄÚµå
1741163

¹èÇÕ È­Çпä¹ý ½ÃÀå : ¾àÁ¦ À¯Çüº°, ¹èÇÕ È¯°æº°, Åõ¿© °æ·Îº°, ȯÀÚ À¯Çüº°, ¾Ï À¯Çüº°, À¯Åë ä³Îº°, ¹èÇÕ ¹æ¹ýº°, Æ÷Àå À¯Çüº°, ±ÔÁ¦ ´ëÀÀº°, Áö¿ªº°

Compounding Chemotherapy Market, By Drug Type, By Compounding Setting, By Route of Administration, By Patient Type, By Cancer Type, By Distribution Channel, By Compounding Method, By Packaging Type, By Regulatory Compliance, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹èÇÕ È­Çпä¹ý ½ÃÀåÀº 2025³â 58¾ï 2,000¸¸ ´Þ·¯, 2032³â¿¡´Â 81¾ï 3,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR)Àº 4.9%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 58¾ï 2,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 4.90% 2032³â ±Ý¾× ¿¹Ãø 81¾ï 3,000¸¸ ´Þ·¯

¹èÇÕÈ­Çпä¹ýÀ̶õ ÀǾàǰ ¼ººÐÀ» ȯÀÚ °³°³ÀÎÀÇ Çʿ信 µû¶ó ¸ÂÃãÇü ¾àǰÀ¸·Î ¸¸µå´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹è°æ¿¡´Â Àü ¼¼°è ¾Ï ¹ßº´·ü Áõ°¡¿Í Ư¼ö ¾à¹° Á¦Á¦¿¡ ´ëÇÑ ¿ä±¸°¡ ÀÖ½À´Ï´Ù. ¾Ï Ä¡·á°¡ ´õ¿í °³ÀÎÈ­µÊ¿¡ µû¶ó È­ÇÕ¹°Àº ȯÀÚ¿¡°Ô ƯÁ¤ Áúº´, »óÅ ¹× ¹Î°¨µµ¿¡ ÀûÇÕÇÑ Á¦Á¦¸¦ Á¦°øÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¾Ï¿¡ °É¸®±â ½¬¿î ³ëÀÎ Áõ°¡, Á¤¹ÐÀÇ·á¿Í Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ½ÃÆÇ ÁßÀÎ ¾à¹°ÀÇ ºÎÁ·Àº Àü ¼¼°èÀûÀ¸·Î º¹ÇÕ È­Çпä¹ý ¼­ºñ½ºÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ

¾Ï, °ñ¼ö Áúȯ, ¸é¿ª°è Áúȯ°ú °°Àº Áúº´ÀÇ À¯º´·ü Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ¼¼°è º¹ÇÕ È­Çпä¹ý ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù. ó¹æ¾à¿¡ ´ëÇÑ ºñ¿ë Áõ°¡¿Í °áÁ¦ Á¤Ã¥ÀÇ º¯È­´Â ¿¹Ãø ±â°£ µ¿¾È ¼¼°è º¹ÇÕ È­Çпä¹ý ½ÃÀåÀÇ ¼ºÀåÀ» ´Ù½Ã ÇÑ ¹ø Áõ°¡½Ãų °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¦Ç°¿¡¼­ ¾òÀ» ¼ö ÀÖ´Â ¼ÒºñÀÚ °Ç°­ ÇýÅà Áõ°¡´Â ¼¼°è º¹ÇÕ È­Çпä¹ý ½ÃÀå¿¡ »õ·Î¿î ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º´¿ø ¹× ÇコÄÉ¾î »ê¾÷¿¡¼­ º¹ÇÕ È­Çпä¹ý Ä¡·á ¹× ÀǾàǰ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå È®´ë°¡ ÃËÁøµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ¾Ï ȯÀÚ ¼ö´Â 2000³â ÀÌÈÄ °ÅÀÇ µÎ ¹è·Î Áõ°¡ÇßÀ¸¸ç, ÇâÈÄ 20³â µ¿¾È 70% ÀÌ»ó Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °³ÀÎ ¸ÂÃãÇü Ä¡·á ¿É¼Ç°ú °¡Ä¡°ü¿¡ µû¸¥ ÀÇ·á ¸ðµ¨¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Á¾¾ç³»°ú °³¾÷ÀǵéÀÌ Á¶Á¦ ¼­ºñ½º¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÈ÷ ¼Ò¾Æ¾Ï¿¡ ´ëÇÑ ½ÃÆÇ ÀǾàǰÀÇ ºÎÁ·Àº ÀÌ ½ÃÀå ÁøÃâ±â¾÷µé¿¡°Ô ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±×·¯³ª ¿À¿°ÀÇ À§Çè, º¹ÀâÇÑ Á¦Á¦ Á¦Á¶ÀÇ ±â¼úÀû ¹®Á¦, ±¹°¡º°·Î Àϰü¼º ¾ø´Â ±ÔÁ¦ ȯ°æÀº ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¾à±¹ Á¶Á¦¿¡¼­ 3D ÇÁ¸°ÆÃÀÇ Àû¿ëÀÌ È®´ëµÊ¿¡ µû¶ó ÇâÈÄ ¸î ³â µ¿¾È ¾à¹° Àü´ÞÀ» °³¼±ÇÏ°í °³º°È­µÈ Åõ¾à ¼³°è¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â »õ·Î¿î ±æÀ» ¿­ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ º¸°í¼­´Â ¼¼°èÀÇ º¹ÇÕ È­Çпä¹ý ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
  • ¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è º¹ÇÕ È­Çпä¹ý ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • È­ÇÕ¹° È­Çпä¹ý ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è º¹ÇÕ È­Çпä¹ý ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° ¹ß¸Å ¹× ½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÀμöÇÕº´(M&A) ½Ã³ª¸®¿À

Á¦4Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • COVID-19 ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
  • °æÁ¦¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå, ¾àÁ¦ À¯Çüº°, 2020-2032³â

  • ¼­·Ð
  • ¼¼Æ÷ »óÇØ¼º ¾àÁ¦
  • È£¸£¸óÁ¦
  • ¸é¿ªÁ¶ÀýÁ¦
  • Ç¥ÀûÄ¡·á
  • ÁöÁö¿ä¹ý ¾à¹°

Á¦6Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå, ¹èÇÕ È¯°æº°, 2020-2032³â

  • ¼­·Ð
  • º´¿ø Á¶Á¦
  • Á¶Á¦ ¾à±¹
  • Àü¹® Ŭ¸®´Ð
  • ȨÄɾî

Á¦7Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â

  • ¼­·Ð
  • Á¤¸Æ³»(IV)
  • °æ±¸
  • ÇÇÇÏ(SC)
  • ±ÙÀ°³»(IM)
  • ô¼ö³»(IT)

Á¦8Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå, ȯÀÚ À¯Çüº°, 2020-2032³â

  • ¼­·Ð
  • ¼ºÀΠȯÀÚ
  • ¼Ò¾Æ ȯÀÚ
  • °í·É ȯÀÚ

Á¦9Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå, ¾Ï À¯Çüº°, 2020-2032³â

  • ¼­·Ð
  • À¯¹æ¾Ï
  • Æó¾Ï
  • ´ëÀå¾Ï
  • Àü¸³¼±¾Ï
  • ¹éÇ÷º´
  • ¸²ÇÁÁ¾
  • ±âŸ ƯÁ¤ ¾Ï À¯Çü

Á¦10Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â

  • ¼­·Ð
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦11Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå, ¹èÇÕ ¹æ¹ýº°, 2020-2032³â

  • ¼­·Ð
  • ¹«±Õ Á¶Á¦
  • ºñ¹«±Õ Á¶Á¦

Á¦12Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå, Æ÷Àå À¯Çüº°, 2020-2032³â

  • ¼­·Ð
  • ¹ÙÀ̾Ë
  • ¾ÚÇÃ
  • ÇÁ¸®ÇÊµå ½Ã¸°Áö
  • º´

Á¦13Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå, ±ÔÁ¦ ´ëÀÀº°, 2020-2032³â

  • ¼­·Ð
  • USP ±ÔÁ¦
  • FDA ±ÔÁ¦
  • EMA ±ÔÁ¦

Á¦14Àå ¹èÇÕ È­Çпä¹ý ½ÃÀå, Áö¿ªº°, 2020-2032³â

  • ¼­·Ð
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ASEAN ±¹°¡
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
    • GCC ±¹°¡
    • À̽º¶ó¿¤
    • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • Áß¾Ó¾ÆÇÁ¸®Ä«
    • ºÏ¾ÆÇÁ¸®Ä«

Á¦15Àå °æÀï ±¸µµ

  • Braun Melsungen AG
  • Fagron NV
  • PharMEDium Services, LLC(AmerisourceBergen Corporation)
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Advanced Pharma, Inc.
  • McGuff Compounding Pharmacy Services, Inc.
  • Central Admixture Pharmacy Services, Inc.(CAPS)
  • Institutional Pharmacy Solutions, LLC
  • Wedgewood Pharmacy
  • Medisca Inc.
  • Dougherty's Holdings, Inc.
  • PharMEDium Services, LLC(AmerisourceBergen Corporation)
  • BioScrip, Inc.

Á¦16Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
LSH 25.06.18

Compounding Chemotherapy Market is estimated to be valued at USD 5.82 Bn in 2025 and is expected to reach USD 8.13 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.9% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 5.82 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 4.90% 2032 Value Projection: USD 8.13 Bn

Compounding chemotherapies refer to the customization of pharmaceutical ingredients into medication tailored to individual patient needs. This has been largely driven by the rise in cancer prevalence worldwide and the need for specialized drug formulations. As cancer treatments become more personalized, compounding plays a crucial role in providing patients with formulations suited to their specific disease, condition, or sensitivity. Growing geriatric population prone to developing cancers, increasing emphasis on precision medicine and targeted therapies, and shortages of commercially available drugs are some of the key factors fueling the adoption of compounding chemotherapy services globally.

Market Dynamics:

The increasing prevalence of illnesses like cancer, bone marrow conditions, and immune system problems will continue to fuel the growth of the global compounding chemotherapy market over the forecast period. Increasing costs for prescription drugs and changing payment policies are again expected to augment global compounding chemotherapy market growth over the forecast period. Rising consumer health benefits from the products will create new opportunities for the global compounding chemotherapy market. Hospitals and the healthcare industry are becoming more aware of compounded chemotherapy treatments or medicines, which is also assisting in the market's expansion.

According to the World Health Organization, the cancer burden has nearly doubled since 2000 and is expected to grow by over 70% in the next two decades. Increased awareness about personalized treatment options and value-based healthcare models is encouraging oncology practitioners to adopt compounding services. The shortage of commercially manufactured drugs, especially for pediatric cancer, also presents growth opportunities for players in this market. However, risks of contamination, technical challenges in preparing complex formulations, and an inconsistent regulatory environment across countries could hinder the market expansion to some extent. The growing application of 3D printing in pharmacy compounding is likely to open up new avenues, allowing for improved drug delivery and personalized dosage designs in the coming years.

Key features of the study:

  • This report provides in-depth analysis of the global compounding chemotherapy market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global compounding chemotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include B. Braun Melsungen AG, Fagron NV, PharMEDium Services, LLC (AmerisourceBergen Corporation), Baxter International Inc., Fresenius Kabi AG, Advanced Pharma, Inc., McGuff Compounding Pharmacy Services, Inc., Central Admixture Pharmacy Services, Inc. (CAPS), Institutional Pharmacy Solutions, LLC, Wedgewood Pharmacy, Medisca Inc., Dougherty's Holdings, Inc., PharMEDium Services, LLC (AmerisourceBergen Corporation), BioScrip, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global compounding chemotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global compounding chemotherapy market

Global Compounding Chemotherapy Market Detailed Segmentation:

  • By Drug Type:
    • Cytotoxic Drugs
    • Hormonal Agents
    • Immunomodulatory Agents
    • Targeted Therapies
    • Supportive Care Drugs
  • By Compounding Setting:
    • Hospital Compounding
    • Compounding Pharmacies
    • Specialty Clinics
    • Homecare Settings
  • By Route of Administration:
    • Intravenous (IV)
    • Oral
    • Subcutaneous (SC)
    • Intramuscular (IM)
    • Intrathecal (IT)
  • By Patient Type:
    • Adult Patients
    • Pediatric Patients
    • Geriatric Patients
  • By Cancer Type:
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Leukemia
    • Lymphoma
    • Other specific cancer types
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Compounding Method:
    • Aseptic Compounding
    • Non-aseptic Compounding
  • By Packaging Type:
    • Vials
    • Ampoules
    • Pre-filled Syringes
    • Bottles
  • By Regulatory Compliance:
    • USP Chapter <797> Compliance
    • FDA Regulations
    • EMA Regulations
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profile:
    • B.Braun Melsungen AG
    • Fagron NV
    • PharMEDium Services, LLC (AmerisourceBergen Corporation)
    • Baxter International Inc.
    • Fresenius Kabi AG
    • Advanced Pharma, Inc.
    • McGuff Compounding Pharmacy Services, Inc.
    • Central Admixture Pharmacy Services, Inc. (CAPS)
    • Institutional Pharmacy Solutions, LLC
    • Wedgewood Pharmacy
    • Medisca Inc.
    • Dougherty's Holdings, Inc.
    • BioScrip, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Compounding Chemotherapy, By Drug Type
    • Market Compounding Chemotherapy, By Compounding Setting
    • Market Compounding Chemotherapy, By Route of Administration
    • Market Compounding Chemotherapy, By Patient Type
    • Market Compounding Chemotherapy, By Cancer Type
    • Market Compounding Chemotherapy, By Distribution Channel
    • Market Compounding Chemotherapy, By Compounding Method
    • Market Compounding Chemotherapy, By Packaging Type
    • Market Compounding Chemotherapy, By Regulatory Compliance
    • Market Compounding Chemotherapy, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing demand for Personalized Medicine
  • Increasing prevalence of illnesses like cancer
    • Restraints
  • The High cost of compounding chemotherapeutic products
    • Opportunities
  • Rising consumer health benefits from the products
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Compounding Chemotherapy Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Compounding Chemotherapy Market, By Drug Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Cytotoxic Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Hormonal Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Immunomodulatory Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Targeted Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Supportive Care Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Compounding Chemotherapy Market, By Compounding Setting, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Hospital Compounding
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Compounding Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Homecare Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Compounding Chemotherapy Market, By Route of Administration, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Intravenous (IV)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Subcutaneous (SC)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Intramuscular (IM)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Intrathecal (IT)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Compounding Chemotherapy Market, By Patient Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Adult Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Pediatric Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Geriatric Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Compounding Chemotherapy Market, By Cancer Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Leukemia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Lymphoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other specific cancer types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

10. Compounding Chemotherapy Market, By Distribution Channel, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

11. Compounding Chemotherapy Market, By Compounding Method, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Aseptic Compounding
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Non-aseptic Compounding
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

12. Compounding Chemotherapy Market, By Packaging Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Ampoules
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Pre-filled Syringes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Bottles
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

13. Compounding Chemotherapy Market, By Regulatory Compliance, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • USP Chapter <797> Compliance
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • FDA Regulations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • EMA Regulations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

14. Compounding Chemotherapy Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Country 2021-2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Method, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Regulatory Compliance, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Method, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Regulatory Compliance, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Method, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Regulatory Compliance, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Method, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Regulatory Compliance, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Method, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Regulatory Compliance, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Setting, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Compounding Method, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Regulatory Compliance, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
      • South Africa
      • Central Africa
      • North Africa

15. Competitive Landscape

  • Braun Melsungen AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fagron NV
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • PharMEDium Services, LLC (AmerisourceBergen Corporation)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Baxter International Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Fresenius Kabi AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Advanced Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • McGuff Compounding Pharmacy Services, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Central Admixture Pharmacy Services, Inc. (CAPS)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Institutional Pharmacy Solutions, LLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Wedgewood Pharmacy
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Medisca Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Dougherty's Holdings, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • PharMEDium Services, LLC (AmerisourceBergen Corporation)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • BioScrip, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

16. Section

  • Research Methodology
  • About us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦